Elaprase 2 mg/ml concentrate for solution for infusion

DRUG2 trials

Sponsors

Denali Therapeutics Inc., Jcr Pharmaceuticals Co. Ltd.

Conditions

Hunter SyndromeMucopolysaccharidosis Type II [MPS II]Mucopolysaccharidosis type II

Phase 2

A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II

RecruitingCTIS2024-510990-21-00

Denali Therapeutics Inc.Mucopolysaccharidosis Type II [MPS II]

Start: 2022-11-11Target: 32Updated: 2025-09-11

Phase 3

A PHASE III STUDY OF JR-141 IN MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER SYNDROME) PATIENTS

Active, not recruitingCTIS2024-512289-33-00

Jcr Pharmaceuticals Co. Ltd.Hunter Syndrome, Mucopolysaccharidosis type II

Start: 2022-08-24Target: 35Updated: 2025-11-13